Federica Palermo

648 total citations
12 papers, 110 citations indexed

About

Federica Palermo is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Cancer Research. According to data from OpenAlex, Federica Palermo has authored 12 papers receiving a total of 110 indexed citations (citations by other indexed papers that have themselves been cited), including 9 papers in Oncology, 6 papers in Pulmonary and Respiratory Medicine and 5 papers in Cancer Research. Recurrent topics in Federica Palermo's work include Colorectal Cancer Treatments and Studies (9 papers), Gastric Cancer Management and Outcomes (6 papers) and Cancer Genomics and Diagnostics (4 papers). Federica Palermo is often cited by papers focused on Colorectal Cancer Treatments and Studies (9 papers), Gastric Cancer Management and Outcomes (6 papers) and Cancer Genomics and Diagnostics (4 papers). Federica Palermo collaborates with scholars based in Italy, Germany and United Kingdom. Federica Palermo's co-authors include Sara Lonardi, Alessandra Raimondi, Michele Prisciandaro, Filippo Pietrantonio, Francesca Bergamo, Floriana Nappo, Antonia Strippoli, Giovanni Gerardo Cardellino, Giovanni Randon and Sabina Murgioni and has published in prestigious journals such as Journal of Clinical Oncology, Annals of Oncology and European Journal of Cancer.

In The Last Decade

Federica Palermo

12 papers receiving 110 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Federica Palermo Italy	4	69	67	50	34	31	12	110
Jane V. Thomas United States	5	34 0.5×	87 1.3×	48 1.0×	51 1.5×	25 0.8×	15	123
Stefan Angermeier Germany	6	138 2.0×	94 1.4×	98 2.0×	24 0.7×	60 1.9×	28	182
Mohammad Aburahmah Saudi Arabia	4	80 1.2×	44 0.7×	72 1.4×	64 1.9×	25 0.8×	9	129
Kyriakos Kouvelakis United Kingdom	5	65 0.9×	64 1.0×	51 1.0×	22 0.6×	23 0.7×	11	127
Maria Kuiper Netherlands	3	40 0.6×	86 1.3×	21 0.4×	38 1.1×	9 0.3×	5	104
Brittanie M Millang United States	7	54 0.8×	78 1.2×	58 1.2×	12 0.4×	16 0.5×	8	115
Takahiro Utsumi Japan	7	83 1.2×	112 1.7×	58 1.2×	41 1.2×	17 0.5×	21	159
José Díaz-Tasende Spain	7	83 1.2×	71 1.1×	58 1.2×	46 1.4×	31 1.0×	23	144

Countries citing papers authored by Federica Palermo

Since Specialization

Citations

This map shows the geographic impact of Federica Palermo's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Federica Palermo with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Federica Palermo more than expected).

Fields of papers citing papers by Federica Palermo

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Federica Palermo. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Federica Palermo. The network helps show where Federica Palermo may publish in the future.

Co-authorship network of co-authors of Federica Palermo

This figure shows the co-authorship network connecting the top 25 collaborators of Federica Palermo. A scholar is included among the top collaborators of Federica Palermo based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Federica Palermo. Federica Palermo is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

12 of 12 papers shown

Ambrosini, Margherita, Alessandra Raimondi, Giovanna Sabella, et al.. (2025). Preoperative botensilimab (BOT) with or without balstilimab (BAL) for patients with resectable locally advanced pMMR or dMMR colon cancer: Results from the UNICORN trial by GONO.. Journal of Clinical Oncology. 43(4_suppl). 158–158. 1 indexed citations

Cremolini, Chiara, Filippo Pietrantonio, Sara Lonardi, et al.. (2025). Panitumumab retreatment followed by regorafenib versus the reverse sequence in chemorefractory metastatic colorectal cancer patients with RAS and BRAF wild-type circulating tumor DNA (ctDNA): Results of the phase II randomized PARERE trial by GONO.. Journal of Clinical Oncology. 43(17_suppl). 1 indexed citations

Nappo, Floriana, Matteo Fassan, Elisa Giommoni, et al.. (2024). LBA4 Switch maintenance with ramucirumab plus paclitaxel versus continuation of oxaliplatin-based chemotherapy in advanced HER2-negative gastric or gastroesophageal junction (GEJ) cancer: Final results and key biomarkers of the ARMANI phase III trial. Annals of Oncology. 35. S214–S214. 1 indexed citations

Pietrantonio, Filippo, Giovanni Randon, Sara Lonardi, et al.. (2024). Ramucirumab plus paclitaxel as switch maintenance versus continuation of oxaliplatin-based chemotherapy in patients (pts) with advanced HER2-negative gastric or gastroesophageal junction (GEJ) cancer: The ARMANI phase III trial.. Journal of Clinical Oncology. 42(17_suppl). LBA4002–LBA4002. 3 indexed citations

Raimondi, A., Federica Palermo, Federica Morano, et al.. (2024). 498TiP Adjuvant trastuzumab deruxtecan plus fluoropyrimidine versus standard chemotherapy in HER2-positive gastric or gastroesophageal cancer patients with persistence of minimal residual disease in liquid biopsy after pre-operative chemotherapy and radical surgery: The TRINITY trial. Annals of Oncology. 35. S198–S199. 1 indexed citations

Raimondi, A., Sara Lonardi, Sabina Murgioni, et al.. (2024). 423P Multicentre, multi-cohort, single-arm phase II trial of tremelimumab and durvalumab as neoadjuvant or definitive treatment of patients (pts) with microsatellite instability-high (MSI) resectable gastric or gastroesophageal junction adenocarcinoma (GAC/GEJAC): The INFINITY study. Annals of Oncology. 35. S172–S172. 1 indexed citations

Raimondi, Alessandra, Federico Nichetti, Arndt Stahler, et al.. (2023). Optimal maintenance strategy following FOLFOX plus anti-EGFR induction therapy in patients with RAS wild type metastatic colorectal cancer: An individual patient data pooled analysis of randomised clinical trials. European Journal of Cancer. 190. 112945–112945. 7 indexed citations

Boccaccino, Alessandra, Daniele Rossini, Alessandra Raimondi, et al.. (2023). Adverse events during first-line treatments for mCRC: The Toxicity over Time (ToxT) analysis of three randomised trials. European Journal of Cancer. 189. 112910–112910. 2 indexed citations

Pietrantonio, Filippo, Alessandra Raimondi, Sara Lonardi, et al.. (2023). INFINITY: A multicentre, single-arm, multi-cohort, phase II trial of tremelimumab and durvalumab as neoadjuvant treatment of patients with microsatellite instability-high (MSI) resectable gastric or gastroesophageal junction adenocarcinoma (GAC/GEJAC).. Journal of Clinical Oncology. 41(4_suppl). 358–358. 68 indexed citations

10.

Antoniotti, Carlotta, Daniele Rossini, Filippo Pietrantonio, et al.. (2023). FOLFOXIRI plus bevacizumab and atezolizumab as upfront treatment of unresectable metastatic colorectal cancer (mCRC): Updated and overall survival results of the phase II randomized AtezoTRIBE study.. Journal of Clinical Oncology. 41(16_suppl). 3500–3500. 8 indexed citations

11.

Pietrantonio, Filippo, Federica Morano, Sara Lonardi, et al.. (2021). 383O MAYA trial: Temozolomide (TMZ) priming followed by combination with low-dose ipilimumab and nivolumab in patients with microsatellite stable (MSS), MGMT silenced metastatic colorectal cancer (mCRC). Annals of Oncology. 32. S530–S531. 15 indexed citations

12.

Palermo, Federica, et al.. (2018). Lipidomics and Nutrylipidomics in Oncology: Review of the Literature. Zenodo (CERN European Organization for Nuclear Research). 1(1). 2 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Jane V. Thomas Breakdown of academic impact, for papers by Stefan Angermeier Breakdown of academic impact, for papers by Mohammad Aburahmah Breakdown of academic impact, for papers by Kyriakos Kouvelakis Breakdown of academic impact, for papers by Maria Kuiper Breakdown of academic impact, for papers by Brittanie M Millang Breakdown of academic impact, for papers by Takahiro Utsumi Breakdown of academic impact, for papers by José Díaz-Tasende